Navigation Links
Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
Date:1/14/2009

view shortening the timeframe for FDA review from 10 months to six months with a target decision date of April 2, 2009.

Formed RIT Oncology, LLC, a 50/50 joint venture with Spectrum, by contributing all assets exclusively related to the Zevalin product in exchange for $15 million in payments to CTI and a 50% membership interest in the joint venture. CTI may also receive up to an additional $15 million in product sales milestones payments upon achievement by the joint venture of certain revenue targets. The partnership will enable CTI to deploy a larger combined sales and marketing team to accelerate top-line product revenues in the near- term and reduce costs to develop Zevalin for new growth opportunities, and could help realize a successful first-line consolidation launch in 2009 and beyond if the Zevalin sBLA is approved. The new joint venture will initially double the sales force and marketing operations for Zevalin in the U.S.

Successfully achieved the primary efficacy endpoint in our pivotal phase III study of pixantrone in relapsed aggressive non-Hodgkin's lymphoma and have scheduled pre-NDA meeting with the FDA in early 2009.

Submitted a marketing authorization application (MAA) to the European Medicines Agency for OPAXIO for first-line treatment of patients with non- small cell lung cancer with ECOG (Eastern Cooperative Oncology Group) performance status 2 (PS2). OPAXIO is a drug candidate which is exclusively partnered with Novartis.

Reduced net cash used for operating activities for the reported nine months ended September 30, 2008 while maintaining key milestone timelines.

Raised significant operating capital to fund operations resulting in advancement of our product portfolio and strategic initiatives in a challenging economic and capital market environment. Even with this additional capital, CTI expects that it will need to access additional capital in 2009 t
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), is pleased to announce that ... has added two more  consultants to its team ... PPL-003 uses a new proprietary cell permeable peptide ... its anti-inflammatory cargo into the eye. ...
(Date:9/23/2014)... , September 23, 2014 ... Closed System Transfer     Devices  (CSTD) ... partnership with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s leading ... Taiwan , China ... the company continues to expand globally, and throughout ...
(Date:9/23/2014)... New York (PRWEB) September 23, 2014 ... from around the globe will convene at ... International Conference, to be held October 26-28 ... in evidence-based research and practice in individualized ... physicians, scientists, researchers, nurses, psychologists, nutritionists, naturopaths, ...
(Date:9/22/2014)... 2014 Pearl's Premium Ultra Low Maintenance ... tolerant grass seed this week with the release of ... coincides with the fact that it is time to ... believe. , As of the date 6/4/13, Pearl's ... by industry experts and the media including: The ...
Breaking Biology Technology:Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2
... BRISBANE, Australia and SEATTLE, Feb. 24 Implicit,Bioscience ... antibody IC14 from Eli Lilly and Company. Implicit ... to Lilly. Lilly will also,receive a royalty on ... "Implicit Bioscience brings substantial expertise and passion to ...
... Feb. 24 Nektar Therapeutics,(Nasdaq: NKTR ... fourth quarter and,year ended December 31, 2008. , ... year for Nektar," said Howard W. Robin,President and ... unique polymer,conjugation chemistry platform, we advanced numerous proprietary ...
... proteinTHOUSAND OAKS, Calif., Feb. 24 Bone Biologics, Inc. ... Aragen Bioscience, has completed development of a recombinant cell ... protein. Bone Biologics has been developing the protein as ... years of research in the lab performed by the ...
Cached Biology Technology:Implicit Licenses Clinical Stage Antibody Program From Lilly 2Implicit Licenses Clinical Stage Antibody Program From Lilly 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 7Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 8Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 9Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences 2
(Date:9/22/2014)... Manufacturing biofuels from food crop by-products such as straw ... work of scientists in the UK and France. ... Research Council (BBSRC) have discovered variant straw plants whose ... biofuels, but which are not significantly smaller or weaker ... ease pressure on global food security as biofuels from ...
(Date:9/22/2014)... their own "antifreeze" proteins to survive in the ... effect, researchers report: The protein-bound ice crystals that ... temperatures warm. , The finding is reported ... of Sciences . , "We discovered what appears ... of antifreeze proteins in Antarctic notothenioid fishes," said ...
(Date:9/22/2014)... of seven institutions in the country selected by ... this year,s BEST Award a $2 million ... most promising biomedical sciences graduate trainees to career ... they have traditionally taken. , The award funds ... Biomedical Scientists (iJOBs) program. It includes courses, seminars, ...
Breaking Biology News(10 mins):Plant variants point the way to improved biofuel production 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3
... relatively common to come across petrol stations surrounded by houses, ... (UM) have studied the effects of contamination at petrol stations ... in buildings less than 100 metres from the service stations. ... increases the risk of cancer have been recorded at ...
... has been awarded a $2.3 million grant by the ... focusing on developing a novel stem cell based therapy ... studying human induced pluripotent stem (iPS) cells derived from ... in the lab and investigate the role of inflammation ...
... not-so-distant evolutionary past, stress often meant imminent danger, ... of our body,s stress response is to stock-pile ... Unit (MMPU), a collaboration between the European Molecular ... University of Heidelberg Medical Centre, have discovered how ...
Cached Biology News:Petrol stations pollute their immediate surroundings 2Stem cell leader awarded $2.3 million grant for Parkinson's 2Blood-clotting protein linked to cancer and septicemia 2Blood-clotting protein linked to cancer and septicemia 3
IHC detection kit for PCNA in cells and tissues...
Request Info...
... Immunogen: Synthetic peptide derived from ... WNT1 protein. Specificity: Reacts with ... Reactivity: Human Mouse (positive controls: ... cell lysates and mouse Mouse-1 cell ...
... Nick Translation System is ideal for both ... Nick Translation System: Provides five pre-mixed ... incorporation Yields >10 8 cpm/g ... DNA to monitor the performance of the ...
Biology Products: